AAAAAA

   
Results: 1-25 | 26-45
Results: 1-25/45
Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART
Authors: Monforte, AD Bugarini, R Pezzotti, P De Luca, A Antinori, A Mussini, C Vigevani, GM Tirelli, U Bruno, R Gritti, F Piazza, M Chigiotti, S Chirianni, A De Stefano, C Pizzigallo, E Perrella, O Moroni, M
Citation: Ad. Monforte et al., Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART, J ACQ IMM D, 28(2), 2001, pp. 114-123
Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?
Authors: Babiker, A Darbyshire, N Pezzotti, P Porter, K Rezza, G Walker, S Beral, V Coutinho, R Del Amo, J Gill, N Lee, C Meyer, L Tyrer, F Dabis, F Thiebaut, R Lawson-Ayayi, S Meyer, L Boufassa, F Hamouda, O Lorenzo, JI Touloumi, G Hatzakis, A Karafoulidou, A Katsarou, O Brettle, R del Romero, J Prins, M Coutinho, RA van Benthem, B Coutinho, RA Kirk, O Pedersen, C Aguado, IH Perez-Hoyos, S Eskild, A Bruun, JN Sannes, M Sabin, C Johnson, AM Phillips, AN Darbyshire, JH Francioli, P Vanhems, P Egger, M Rickenbach, M Cooper, D Kaldor, J Vizzard, J Tusell, JM Ruiz, I Cayla, JA de Olalla, PG Day, NE De Angelis, D
Citation: A. Babiker et al., Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?, J ACQ IMM D, 28(2), 2001, pp. 158-165
Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxiswithin a randomized clinical trial
Authors: Murri, R Ammassari, A Pezzotti, P Cingolani, A De Luca, A Pallavicini, F Grillo, R Antinori, A
Citation: R. Murri et al., Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxiswithin a randomized clinical trial, J ACQ IMM D, 27(1), 2001, pp. 49-55
Response to highly active antiretroviral therapy according to duration of HIV infection
Authors: Pezzotti, P Pappagallo, M Phillips, PN Boros, S Valdarchi, C Sinicco, A Zaccarelli, M Rezza, G
Citation: P. Pezzotti et al., Response to highly active antiretroviral therapy according to duration of HIV infection, J ACQ IMM D, 26(5), 2001, pp. 473-479
Different pattern of AIDS-defining diseases in persons responding to highly active antiretroviral therapy
Authors: Wagner, TM Pezzotti, P Valdarchi, C Rezza, G
Citation: Tm. Wagner et al., Different pattern of AIDS-defining diseases in persons responding to highly active antiretroviral therapy, J ACQ IMM D, 26(4), 2001, pp. 394-395
The influence of hemocoagulative disorders on the outcome of children withhead injury
Authors: Chiaretti, A Pezzotti, P Mestrovic, J Piastra, M Polidori, G Storti, S Velardi, F Di Rocco, C
Citation: A. Chiaretti et al., The influence of hemocoagulative disorders on the outcome of children withhead injury, PED NEUROS, 34(3), 2001, pp. 131-137
Monitoring the trend of the transmission rate of vertically acquired HIV infection: a simple method applied to Italian data
Authors: Girardi, E Rava, L Pezzotti, P Puro, V Ippolito, G
Citation: E. Girardi et al., Monitoring the trend of the transmission rate of vertically acquired HIV infection: a simple method applied to Italian data, J BIOL REG, 15(3), 2001, pp. 229-234
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study
Authors: Lepri, AC Phillips, AN Monforte, AD Castelli, F Antinori, A de Luca, A Pezzotti, P Alberici, F Cargnel, A Grima, P Piscopo, R Prestileo, T Scalise, G Vigevani, M Moroni, M
Citation: Ac. Lepri et al., When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study, AIDS, 15(8), 2001, pp. 983-990
Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens
Authors: Dorrucci, M Pezzotti, P Grisorio, B Minardi, C Muro, MS Vullo, V Monforte, AD
Citation: M. Dorrucci et al., Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens, AIDS, 15(13), 2001, pp. 1733-1736
Absence of an effect of herpes simplex virus type 2 infection on HIV disease progression: data from a cohort of HIV-positive individuals with known date of seroconversion
Authors: Suligoi, B Dorrucci, M Volpi, A Andreoni, M Pezzotti, P Rezza, G
Citation: B. Suligoi et al., Absence of an effect of herpes simplex virus type 2 infection on HIV disease progression: data from a cohort of HIV-positive individuals with known date of seroconversion, AIDS, 15(1), 2001, pp. 133-135
Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients
Authors: Andreoni, M Goletti, D Pezzotti, P Pozzetto, A Monini, P Sarmati, L Farchi, F Tisone, G Piazza, A Pisani, F Angelico, M Leone, P Citterio, F Ensoli, B Rezza, G
Citation: M. Andreoni et al., Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients, J INFECTION, 43(3), 2001, pp. 195-199
Secondary mutations in the protease region of human immunodeficiency virusand virologic failure in drug-naive patients treated with protease inhibitor-based therapy
Authors: Perno, CF Cozzi-Lepri, A Balotta, C Forbici, F Violin, M Bertoli, A Facchi, G Pezzotti, P Cadeo, G Tositti, G Pasquinucci, S Pauluzzi, S Scalzini, A Salassa, B Vincenti, A Phillips, AN Dianzani, F Appice, A Angarano, G Monno, L Ippolito, G Moroni, M Monforte, AD
Citation: Cf. Perno et al., Secondary mutations in the protease region of human immunodeficiency virusand virologic failure in drug-naive patients treated with protease inhibitor-based therapy, J INFEC DIS, 184(8), 2001, pp. 983-991
Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses
Authors: Conti, S Masocco, M Pezzotti, P Toccaceli, V Vichi, M Boros, S Urciuoli, R Valdarchi, C Rezza, G
Citation: S. Conti et al., Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses, J ACQ IMM D, 25(5), 2000, pp. 451-458
Markov models for HIV disease progression: An unverified assumption
Authors: Dal Maso, L Gava, M Pezzotti, P Torelli, N Franceschi, G
Citation: L. Dal Maso et al., Markov models for HIV disease progression: An unverified assumption, J ACQ IMM D, 25(5), 2000, pp. 466-468
Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection
Authors: Rezza, G Lepri, AC Monforte, AD Pezzotti, P Castelli, F Dianzani, F Lazzarin, A De Luca, A Arlotti, M Leoncini, F Manconi, PE Rizzardini, G Minoli, L Poggio, A Ippolito, G Phillips, AN Moroni, M
Citation: G. Rezza et al., Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection, J ACQ IMM D, 25(1), 2000, pp. 56-62
Antiretroviral combination therapies and AIDS-defining cancers
Authors: Serraino, D Pezzotti, P Boros, S Rezza, G
Citation: D. Serraino et al., Antiretroviral combination therapies and AIDS-defining cancers, J ACQ IMM D, 24(1), 2000, pp. 84-86
Cytotoxin-associated gene A and vacuolating cytotoxin A in human isolates of Helicobacter pylori and their association with the clinical status of ulcer disease
Authors: Carattoli, A Pezzella, C Pietroiusti, A Galante, A Pezzotti, P Luzzi, I
Citation: A. Carattoli et al., Cytotoxin-associated gene A and vacuolating cytotoxin A in human isolates of Helicobacter pylori and their association with the clinical status of ulcer disease, EUR J GASTR, 12(11), 2000, pp. 1207-1213
Antiretroviral therapy in HIV-infected individuals in clinical practice: Are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values?
Authors: Pezzotti, P Monforte, AD Bugarini, R Rezza, G Arici, C Angarano, G Borderi, M Alberici, F Armignacco, O Menichetti, F Prestileo, T Sighinolfi, L Sinicco, A Resta, F Vigevani, M Ippolito, G
Citation: P. Pezzotti et al., Antiretroviral therapy in HIV-infected individuals in clinical practice: Are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values?, EUR J EPID, 16(10), 2000, pp. 919-926
Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
Authors: Monforte, AD Lepri, AC Rezza, G Pezzotti, P Antinori, A Phillips, AN Angarano, G Colangeli, V De Luca, A Ippolito, G Caggese, L Soscia, F Filice, G Gritti, F Narciso, P Tirelli, U Moroni, M
Citation: Ad. Monforte et al., Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients, AIDS, 14(5), 2000, pp. 499-507
Cancer risk among men with, or at risk of, HIV infection in southern Europe
Authors: Serraino, D Boschini, A Carrieri, P Pradier, C Dorrucci, M Dal Maso, L Ballarini, P Pezzotti, P Smacchia, C Pesce, A Ippolito, G Franceschi, S Rezza, G
Citation: D. Serraino et al., Cancer risk among men with, or at risk of, HIV infection in southern Europe, AIDS, 14(5), 2000, pp. 553-559
Effect of ignoring the time of HIV seroconversion in estimating changes insurvival over calendar time in observational studies: results from CASCADE
Authors: Porter, K Babiker, A Walker, S Darbyshire, J Gill, N Beral, V Coutinho, R Darbyshire, J Gill, N Lee, C Meyer, L Rezza, G Porter, K Babiker, A Walker, S Darbyshire, J Tyrer, F Dabis, F Marimoutou, C Meyer, L Boufassa, F Hamouda, O Brunn, M Pezzotti, P Rezza, G Lorenzo, JI Touloumi, G Hatzakis, A Karafoulidou, A Katsarou, O Brettle, R Del Amo, J del Romero, J Prins, M Coutinho, RA van Benthem, B Coutinho, RA Kirk, O Pedersen, C AGuado, IH Perez-Hoyos, S Eskild, A Bruun, JN Sannes, M Sabin, C Lee, C Johnson, AM Phillips, AN Babiker, A Darbyshire, JH Gill, N Porter, K Egger, M Francioli, P Rickenbach, M Cooper, D Kaldor, J Cooper, D Kaldor, J Vizzard, J Tusell, JM Ruiz, I Cayla, JA de Olalla, PG Day, NE De Angelis, D
Citation: K. Porter et al., Effect of ignoring the time of HIV seroconversion in estimating changes insurvival over calendar time in observational studies: results from CASCADE, AIDS, 14(13), 2000, pp. 1899-1906
Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion
Authors: Rezza, G Dorrucci, M Serraino, D Andreoni, M Giuliani, M Zerboni, R Sarmati, L Colangeli, V Salassa, B Monini, P Ensoli, B Pezzotti, P
Citation: G. Rezza et al., Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion, AIDS, 14(11), 2000, pp. 1647-1653
Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon
Authors: Rezza, G Tchangmena, OB Andreoni, M Bugarini, R Toma, L Bakary, DK Glikoutou, M Sarmati, L Monini, P Pezzotti, P Ensoli, B
Citation: G. Rezza et al., Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon, SEX TRA DIS, 27(3), 2000, pp. 159-164
Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis
Authors: Babiker, A Darby, S De Angelis, D Kwart, D Porter, K Beral, V Darbyshire, J Day, N Gill, N Coutinho, R Prins, M van Benthem, B Coutinho, R Dabis, F Marimoutou, C Ruiz, I Tusell, J Altisent, C Evatt, B Jaffe, H Kirk, O Pedersen, C Rosenberg, P Goedert, J Biggar, R Melbye, M Brettie, R Downs, A Hamouda, O Touloumi, G Karafoulidou, A Katsarou, O Donfield, S Gomperts, E Hilgartner, M Hoots, K Schoenbaum, E Beral, V Zangerle, R Del Amo, J Pezzotti, P Rezza, G Hutchinson, S Day, N De Angelis, D Gore, S Kingsley, L Schrager, L Rosenberg, P Goedert, J Melnick, S Koblin, B Eskild, A Bruun, J Sannes, M Evans, B Lepri, AC Sabin, C Buchbinder, S Vittinghoff, E Moss, A Osmond, D Winkelstein, W Goldberg, D Boufassa, F Meyer, L Egger, M Francioli, P Rickenbach, M Cooper, D Tindall, B Sharkey, T Vizzard, J Kaldor, J Cunningham, P Vanhems, P Vizzard, J Kaldor, J Learmont, J Farewell, V Berglund, O Mosley, J Operskalski, E van den Berg, M Metzger, D Tobin, D Woody, G Rusnak, J Hendrix, C Garner, R Hawkes, C Renzullo, P Garland, F Darby, S Ewart, D Giangrande, P Lee, C Phillips, A Spooner, R Wilde, J Winter, M Babiker, A Darbyshire, J Evans, B Gill, N Johnson, A Phillips, A Porter, K Lorenzo, JI Schechter, M
Citation: A. Babiker et al., Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis, LANCET, 355(9210), 2000, pp. 1131-1137
Antiretroviral therapy and mortality among children with perinatal HIV infection - Reply
Authors: Pezzotti, P Rezza, G Balducci, M Tovo, PA Gabiano, C Galli, L de Martino, M
Citation: P. Pezzotti et al., Antiretroviral therapy and mortality among children with perinatal HIV infection - Reply, J AM MED A, 284(22), 2000, pp. 2871-2872
Risultati: 1-25 | 26-45